Latest News and Press Releases
Want to stay updated on the latest news?
-
EXTON, PA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Despite advancements in treatments, sickle cell disease and thalassemia continue to present significant challenges for patients and healthcare providers....
-
EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...
-
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...
-
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
-
EXTON, PA, July 08, 2024 (GLOBE NEWSWIRE) -- Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying...
-
Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That...
-
EXTON, PA, June 26, 2024 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis....
-
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
-
EXTON, PA, June 17, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
-
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...